कंपनी का अवलोकन
Skye Bioscience, Inc. operates as a clinical-stage biotechnology enterprise dedicated to developing small molecules that modulate G-protein-coupled receptors (GPCRs) for the treatment of obesity, overweight conditions, and metabolic diseases. The company functions within the healthcare sector, specifically the biotechnology industry, where it pursues innovative therapeutic solutions rather than immediate revenue generation from established products. Its current market capitalization stands at $23.61M, supported by an employee base of 12 individuals, reflecting a nascent operational scale typical of early-phase biotech firms. This modest market cap combined with the absence of reported annual revenue indicates that the company is in an exploratory phase, relying on future product approvals and clinical trial outcomes to transition from a research-focused entity to a commercially viable business.
वित्तीय स्वास्थ्य
The financial statements reveal a net income of $-55,924,816 and an EBITDA of $-57,440,212, while annual revenue figures are not available in the current reporting period. The significant negative net income relative to the reported EBITDA highlights a substantial cost structure burden, likely driven by the high expenses associated with drug discovery, clinical trial execution, and regulatory compliance that are common in the biotechnology sector. The company reports a free cash flow of $-22,953,560, which signifies a continuous consumption of liquidity necessary to fund its R&D pipeline before any commercial sales commence. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved commercial profitability or that no sales have been recognized to generate a margin. Despite the operational losses, the balance sheet holds $25.74M in cash against a debt obligation of $273,646, with a debt-to-equity ratio of 1.37, suggesting a leveraged position where debt exceeds equity but is managed within a specific capital structure. The current ratio of 3.30 demonstrates a strong short-term liquidity position, as the company possesses more than three times the current assets required to meet its immediate liabilities. Furthermore, the return on equity is -126.8% and the return on assets is -71.9%, metrics that reveal management is currently generating negative returns on the capital invested, a characteristic phase for clinical-stage companies awaiting market entry.
मूल्यांकन आकलन
The valuation metrics present a trailing P/E ratio of N/A and a forward P/E of -0.66, a disparity that implies earnings are currently negative and traditional price-to-earnings models cannot be applied to assess value based on profitability. The price-to-book ratio is 1.18, suggesting that the market values the company's equity at a slight premium over its book value, which is common for firms with intangible assets like intellectual property that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of 0.03, figures that reflect the company's lack of current revenue and earnings, necessitating reliance on asset-based or clinical-pipeline valuations instead of income-based multiples. The stock has traded between a 52-week low of $0.57 and a 52-week high of $5.75, meaning the current valuation fluctuates significantly within this established range depending on market sentiment regarding its pipeline. The beta value is 2.87, indicating that the stock's price volatility is substantially higher than the broader market, exposing investors to greater risk during periods of market turbulence.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet generated sufficient commercial sales to calculate year-over-year growth percentages. Since the growth rates are unavailable, it is impossible to determine if earnings are growing faster or slower than revenue, though the absence of revenue implies the company is pre-revenue. Skye Bioscience, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all available cash to reinvest into its research and development activities rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms, as they prioritize advancing their lead product candidate, nimacimab, through clinical trials over providing immediate income returns. Consequently, the overall growth and income profile is characterized by high capital intensity with zero current income, relying entirely on future clinical success to generate revenue and potential earnings growth in subsequent years.